Your browser doesn't support javascript.
loading
Two types of BCR interactions are positively selected during leukemia development in the Eµ-TCL1 transgenic mouse model of CLL.
Iacovelli, Stefano; Hug, Eva; Bennardo, Sara; Duehren-von Minden, Marcus; Gobessi, Stefania; Rinaldi, Andrea; Suljagic, Mirza; Bilbao, Daniel; Bolasco, Giulia; Eckl-Dorna, Julia; Niederberger, Verena; Autore, Francesco; Sica, Simona; Laurenti, Luca; Wang, Hongsheng; Cornall, Richard J; Clarke, Stephen H; Croce, Carlo M; Bertoni, Francesco; Jumaa, Hassan; Efremov, Dimitar G.
Afiliación
  • Iacovelli S; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Rome, Italy;
  • Hug E; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany;
  • Bennardo S; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Rome, Italy;
  • Duehren-von Minden M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany;
  • Gobessi S; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Rome, Italy;
  • Rinaldi A; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland;
  • Suljagic M; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Rome, Italy;
  • Bilbao D; European Molecular Biology Laboratory, Rome, Italy;
  • Bolasco G; European Molecular Biology Laboratory, Rome, Italy;
  • Eckl-Dorna J; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria;
  • Niederberger V; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria;
  • Autore F; Department of Hematology, Catholic University Hospital "A. Gemelli," Rome, Italy;
  • Sica S; Department of Hematology, Catholic University Hospital "A. Gemelli," Rome, Italy;
  • Laurenti L; Department of Hematology, Catholic University Hospital "A. Gemelli," Rome, Italy;
  • Wang H; Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD;
  • Cornall RJ; Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom;
  • Clarke SH; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC;
  • Croce CM; The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Bertoni F; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland; IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and.
  • Jumaa H; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Institute of Immunology, University Clinics Ulm, Ulm, Germany.
  • Efremov DG; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Rome, Italy;
Blood ; 125(10): 1578-88, 2015 Mar 05.
Article en En | MEDLINE | ID: mdl-25564405
ABSTRACT
Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy characterized by a highly variable course and outcome. The disease is believed to be driven by B-cell receptor (BCR) signals generated by external antigens and/or cell-autonomous BCR interactions, but direct in vivo evidence for this is still lacking. To further define the role of the BCR pathway in the development and progression of CLL, we evaluated the capacity of different types of antigen/BCR interactions to induce leukemia in the Eµ-TCL1 transgenic mouse model. We show that cell autonomous signaling capacity is a uniform characteristic of the leukemia-derived BCRs and represents a prerequisite for CLL development. Low-affinity BCR interactions with autoantigens generated during apoptosis are also positively selected, suggesting that they contribute to the pathogenesis of the disease. In contrast, high-affinity BCR interactions are not selected, regardless of antigen form or presentation. We also show that the capacity of the leukemic cells to respond to cognate antigen correlates inversely with time to leukemia development, suggesting that signals induced by external antigen increase the aggressiveness of the disease. Collectively, these findings provide in vivo evidence that the BCR pathway drives the development and can influence the clinical course of CLL.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos B / Leucemia Linfocítica Crónica de Células B Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos B / Leucemia Linfocítica Crónica de Células B Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article